Immuno-Oncology Literature & Resources

Find critical resources for your immuno-oncology research

Immuno-Oncology Publications

Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells
Boudousquie C., Bossi G., Hurst J., Rygiel K., Jakobsen B., Hassan N. Immunology, 152, 425-38, 2017.

A Treg cell killing suppression assay was carried out using the IncuCyte System to evaluate the IMCgp100 induced killing capacity of Mel526 cell by different CD8+T cell subpopulations. These findings are of particular importance because IMCgp100 is currently undergoing clinical trials as a single agent or in combination with checkpoint inhibitors for patients with malignant melanoma.

Smac mimetics and innate immune stimuli synergize to promote tumor death
Beug S., Tang V., LaCasse E., Cheung H., Beauregard C., Brun J., Nuyens J., Earl N., St-Jean M., Holbrook J., Dastidar H., Mahoney D., Ilkow C., Le Boeuf F., Bell J., Korneluk R. Nature Biotech, 32(2): 182-90, 2014.

Researchers evaluated if stimulating the innate immune system using pathogen mimetics would be a safe and effective strategy to generate a cytokine milieu sufficient to initiate programmed cell death in tumors treated with an SMC. IncuCyte® live-cell analysis was used to determine the kinetics of VSVΔ51 spread and apoptotic cell death.

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Li C., Lim S., Xia W., Lee H., Chan L., Kuo C., Khoo K., Chang S., Cha J., Kim T., Hsu J., Wu Y., Hsu J., Yamaguchi H., Ding Q., Wang Y., Yao J., Lee C., Wu H., Sahin A, Allison J, Yu D., Hortobagyi G, Hung M. Nature Comm, 7: 1-10, 2016.

The IncuCyte® Live-Cell Analysis System was used to evaluate PD-L1 and PD-1 interaction assay, as part of the research to demonstrate a novel interchange between glycosylation and phosphorylation regulating ubiquitination and degradation of PD-L1

The fully synthetic MAG-Tn3 therapeutic vaccine containing the tetanus toxoid-derived TT830-844 universal epitope provides anti-tumor immunity
Laubreton D., Bay S., Sedlik C., Artaud C., Ganneau C, Deriaud E., Viel S., Puaux A., Amigonera S., Gerard C., Lo-Man R., Leclerc C. Cancer Immunology, Immunotherapy, 65(3):315-25, 2016.

Demonstrated the anti-tumor potential of the anti-Tn antibodies induced in response to MAG-Tn3 vaccination and showed their capacity to recognize and mediate killing of tumor cells in vitro and in vivo. The IncuCyte® was used to quantitate complement-dependent cytotoxicity of Jurkat, MCF-7, SHIN3 and OVCAR cell lines.



Immuno-Oncology Help & Support

Questions about our products and services? Need a quote? Get in touch online & one of our team will get back to you promptly.

Contact our technical support team directly

No file selected
0%
Stay up-to-date with what's happening at Essen BioScience

© 2018 Essen BioScience

Privacy Policy